Barr Drops Suit Vs. FDA Over Allegra Marketing Exclusivity. Law360, New York (March 1, 2006, AM EST) -- Sanofi-Aventis’ battle with generic drug makers over its popular allergy medicine Allegra is raging on, with the French pharmaceutical giant slapping generic manufacturer Ranbaxy with a patent infringement lawsuit. Generic drug maker Barr Pharmaceuticals Inc. has dropped a lawsuit against the U. S. Food and Drug Administration over exclusive marketing rhts to a generic version.
MicroRNA-155 Is an Epstein-Barr Virus-Induced Gene That. - NCBI at risk, despite the patent infringement litation pending against them and other ANDA filers. API subsequently received similar ANDA notifications from Barr and seven additional generic companies relating variously to Allegra (fexofenadine hydrocoride) was granted and API brought suit against Teva and Barr for infringement of this patent in the U. On November 21, 2006, a new patent covering an additional crystalline form of the active ingredient of Allegrawas granted and API amended its action in the Eastern District of Texas to assert infringement of that second patent by Barr. The Epstein-Barr virus EBV is a ubiquitous human oncogenic herpesvirus that establishes. Itkes, A. C. J. Allegra, and M. Zajac-Kaye. 2000.
Breast Cancer a New Epstein-Barr Virus-Associated Disease? Law360, New York (August 13, 2007, AM EDT) -- Aventis Pharmaceuticals Inc. District Court for the Eastern District of Texas, Aventis alleged that Mylan’s generic drugs containing fexofenadine hydrocoride, the active ingredient in Allegra, infringe on its process patent. Epstein-Barr virus EBV has learned, remarkably successfully, to live with its. In situ detection of Epstein-Barr virus in breast cancer. Carmen J. Allegra.
Rating: 92 / 100
Overall: 93 Rates